JP2004537308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537308A5 JP2004537308A5 JP2003517084A JP2003517084A JP2004537308A5 JP 2004537308 A5 JP2004537308 A5 JP 2004537308A5 JP 2003517084 A JP2003517084 A JP 2003517084A JP 2003517084 A JP2003517084 A JP 2003517084A JP 2004537308 A5 JP2004537308 A5 JP 2004537308A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- hsv
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 20
- 238000000034 method Methods 0.000 claims 15
- 241000700584 Simplexvirus Species 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 101150090364 ICP0 gene Proteins 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 210000002865 immune cell Anatomy 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 208000009889 Herpes Simplex Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000178270 Canarypox virus Species 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30892301P | 2001-07-31 | 2001-07-31 | |
| US30942801P | 2001-08-01 | 2001-08-01 | |
| PCT/US2002/024306 WO2003011893A2 (en) | 2001-07-31 | 2002-07-31 | Immunologically significant herpes simplex virus antigens and methods for using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004537308A JP2004537308A (ja) | 2004-12-16 |
| JP2004537308A5 true JP2004537308A5 (enExample) | 2006-01-05 |
| JP4519461B2 JP4519461B2 (ja) | 2010-08-04 |
Family
ID=26976523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003517084A Expired - Fee Related JP4519461B2 (ja) | 2001-07-31 | 2002-07-31 | 免疫学的に重要な単純ヘルペスウイルス抗原およびそれを用いる方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6814969B2 (enExample) |
| EP (2) | EP2191845A1 (enExample) |
| JP (1) | JP4519461B2 (enExample) |
| AT (1) | ATE488249T1 (enExample) |
| AU (1) | AU2002317604A1 (enExample) |
| CA (1) | CA2454750C (enExample) |
| DE (1) | DE60238330D1 (enExample) |
| WO (1) | WO2003011893A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60324678D1 (de) | 2002-07-18 | 2008-12-24 | Univ Washington | N t-lymphozyten und damit identifizierte hsv-antigene |
| US8541002B2 (en) | 2003-09-12 | 2013-09-24 | Agenus Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
| CA2605078C (en) * | 2005-04-15 | 2013-01-08 | Human Matrix Sciences, Llc | Plant-derived elastin binding protein ligands and methods of using the same |
| CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| US7628993B2 (en) | 2006-07-20 | 2009-12-08 | Vical Incorporated | Compositions and methods for vaccinating against HSV-2 |
| DE112008000888T5 (de) | 2007-04-04 | 2011-05-19 | Hugh Birchwood McTavish | Nichtspezifische verzögerte Überempfindlichkeitsreaktion zur Behandlung von Herpes-Simplex-Virusinfektionen |
| ES2588705T3 (es) * | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| CA2723918C (en) | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| US8460674B2 (en) * | 2009-02-07 | 2013-06-11 | University Of Washington | HSV-1 epitopes and methods for using same |
| EP2413950A4 (en) | 2009-04-03 | 2013-05-01 | Univ Washington | ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF |
| RU2585961C9 (ru) * | 2009-05-22 | 2016-12-27 | Дженосеа Биосайенсиз Инк. | Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа |
| WO2012061637A2 (en) * | 2010-11-03 | 2012-05-10 | University Of Washington | Hsv-1 epitopes and methods for using same |
| JP6055776B2 (ja) | 2010-11-24 | 2016-12-27 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 |
| IN2014CN02581A (enExample) | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| JP6199878B2 (ja) | 2011-11-23 | 2017-09-20 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法 |
| SMT201800368T1 (it) | 2012-05-16 | 2018-09-13 | Immune Design Corp | Vaccini per l'infezione da virus-2 herpes simplex |
| AU2016225025B2 (en) | 2015-02-26 | 2020-07-16 | Squarex, Llc | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection |
| JP2019512501A (ja) * | 2016-03-14 | 2019-05-16 | レッドバイオテック・アーゲーＲｅｄｂｉｏｔｅｃ Ａｇ | Ｈｓｖを処置するための手段及び方法 |
| EP3519427A4 (en) | 2016-09-28 | 2020-03-11 | Genocea Biosciences Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES |
| WO2019018796A1 (en) * | 2017-07-21 | 2019-01-24 | Fred Hutchinson Cancer Research Center | VACCINE EPITOPES AGAINST HERPES SIMPLEX VIRUS RECOGNIZED SPECIFICALLY BY MEMORY T LYMPHOCYTES RESIDING IN FABRICS |
| CN112710849A (zh) * | 2020-12-24 | 2021-04-27 | 首都医科大学附属北京友谊医院 | 一种鉴定抗EBV免疫活性的ELISpot试剂盒、制备方法及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859587A (en) | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA2088600C (en) | 1990-08-02 | 1999-11-16 | Rae L. Burke | Herpes simplex virus vp16 vaccines |
| CA2090295A1 (en) | 1992-02-03 | 1993-08-04 | Anthony B. Nesburn | Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| AU705563B2 (en) | 1995-07-28 | 1999-05-27 | Marie Curie Cancer Care | Transport proteins and their uses |
| GB9615726D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Anti-viral agent 11 |
| CA2270282A1 (en) | 1996-11-04 | 1998-05-14 | Smithkline Beecham Corporation | Novel coding sequences from herpes simplex virus type-2 |
| US6017735A (en) * | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
| CA2291010A1 (en) * | 1997-06-02 | 1998-12-10 | Chiron Corporation | Herpes simplex virus vp22 vaccines and methods of use |
| CN1348463A (zh) | 1998-08-07 | 2002-05-08 | 华盛顿大学 | 免疫学单纯疱疹病毒抗原及其使用方法 |
| JP2003512305A (ja) * | 1999-09-30 | 2003-04-02 | ユニバーシティ オブ ワシントン | 免疫学的に重要な単純疱疹ウイルス抗原 |
| US6821519B2 (en) * | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| US6537555B2 (en) * | 2000-06-29 | 2003-03-25 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
-
2002
- 2002-07-31 CA CA2454750A patent/CA2454750C/en not_active Expired - Fee Related
- 2002-07-31 JP JP2003517084A patent/JP4519461B2/ja not_active Expired - Fee Related
- 2002-07-31 AU AU2002317604A patent/AU2002317604A1/en not_active Abandoned
- 2002-07-31 US US10/210,428 patent/US6814969B2/en not_active Expired - Fee Related
- 2002-07-31 DE DE60238330T patent/DE60238330D1/de not_active Expired - Lifetime
- 2002-07-31 EP EP10151241A patent/EP2191845A1/en not_active Withdrawn
- 2002-07-31 WO PCT/US2002/024306 patent/WO2003011893A2/en not_active Ceased
- 2002-07-31 AT AT02748276T patent/ATE488249T1/de not_active IP Right Cessation
- 2002-07-31 EP EP02748276A patent/EP1420821B8/en not_active Expired - Lifetime
-
2004
- 2004-06-30 US US10/882,074 patent/US7037509B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006501825A5 (enExample) | ||
| CA2454750A1 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
| US20180207261A1 (en) | Human herpesvirus immunotherapy | |
| CA2596274A1 (en) | Recombinant mva virus, and the use thereof | |
| CA2534911A1 (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| WO2001023414B1 (en) | Immunologically significant herpes simplex virus antigens | |
| CN105497886A (zh) | 乙肝核心抗原病毒样颗粒作为肿瘤治疗性疫苗载体的应用 | |
| JP2021523127A5 (enExample) | ||
| CN115894708B (zh) | 一种人巨细胞病毒抗原表位嵌合肽及其应用 | |
| CN111032681A (zh) | 修饰型HSV gB蛋白及包含其的HSV疫苗 | |
| Ferru et al. | Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni | |
| JP2009501012A5 (enExample) | ||
| JP2002516662A5 (enExample) | ||
| JP2002522039A5 (enExample) | ||
| CN115850398B (zh) | 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用 | |
| TWI634899B (zh) | 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物 | |
| CA3155370A1 (en) | Improved vaccines for recurrent respiratory papillomatosis and methods for using the same | |
| Li et al. | Immunogenic characterization and protection against Streptococcus mutans infection induced by intranasal DNA prime–protein boost immunization | |
| CN117304274A (zh) | 一种自组装纳米颗粒蛋白、非洲猪瘟多价疫苗及其制备方法和应用 | |
| CN101891825B (zh) | 乙肝核心蛋白与结核抗原或抗原片段的重组融合蛋白及用途 | |
| Ibraheem et al. | Investigation The Effect of Pfizer, AstraZeneca, and Sinopharm Vaccines Against SARS-CoV-2 in Iraq Using Cluster of Differentiation 4 (CD4) and Vitamin D3 | |
| EP3432923B1 (en) | Hcv vaccines | |
| CN107648602B (zh) | 二价乙肝疫苗及其制备方法 | |
| WO2025103370A1 (zh) | 包含冠状病毒的保守重组蛋白片段的疫苗组合物及其应用 |